Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jul 21, 2026, 11:01 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Veno-occlusive Disease Clear all
Completed Not applicable Interventional Results available

Anesthesia Preference for Intravitreal Injection: Topical or Subconjunctival

NCT01640171
View directory record Official record
Conditions
Age-related Macular Degeneration, Central Retinal Vein Occlusion, Diabetic Macular Edema
Interventions
Xylocaine 2% Injectable Anesthetic, Proparacaine Hydrochloride 0.5% Drop, Tetravisc 0.5% Gel, Acuvail, Intra-vitreal Anti-VEGF Drug
Procedure · Drug
Lead sponsor
Retina Vitreous Associates of Florida
Other
Eligibility
18 Years and older
Enrollment
57 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
1
States / cities
Clearwater, Florida
Source: ClinicalTrials.gov public record
Updated Apr 20, 2014 · Synced Jul 21, 2026, 11:01 AM EDT
Completed Phase 2 Interventional Results available

Suprachoroidal Injection of Triamcinolone Acetonide With IVT Aflibercept in Subjects With Macular Edema Following RVO

NCT02303184
View directory record Official record
Conditions
Macular Edema, Retinal Vein Occlusion
Interventions
4 mg CLS-TA, Sham, IVT aflibercept
Drug
Lead sponsor
Clearside Biomedical, Inc.
Industry
Eligibility
18 Years and older
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
14
States / cities
Phoenix, Arizona • Beverly Hills, California • San Diego, California + 11 more
Source: ClinicalTrials.gov public record
Updated Feb 7, 2021 · Synced Jul 21, 2026, 11:01 AM EDT
Withdrawn Phase 4 Interventional

Validating Ultrasound Biomarkers for Hepatic Sinusoidal Obstruction Syndrome in Pediatric Hematopoietic Cell Transplant Patients

NCT03963999
View directory record Official record
Conditions
Sinusoidal Obstruction Syndrome, Veno Occlusive Disease, Hepatic, Bone Marrow Transplant Complications, Stem Cell Transplant Complications
Interventions
Ultrasound Elastography, Contrast Enhanced Ultrasound (CEUS)
Diagnostic Test · Drug
Lead sponsor
Children's Mercy Hospital Kansas City
Other
Eligibility
1 Month to 25 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2025
U.S. locations
1
States / cities
Kansas City, Missouri
Source: ClinicalTrials.gov public record
Updated Jan 12, 2020 · Synced Jul 21, 2026, 11:01 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Effects of Miconazole on Blood Flow

NCT00004575
View directory record Official record
Conditions
Healthy
Interventions
Miconazole, L-NMMA, Bradykinin
Drug
Lead sponsor
National Heart, Lung, and Blood Institute (NHLBI)
NIH
Eligibility
Not listed
Enrollment
15 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2000 – 2001
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 3, 2008 · Synced Jul 21, 2026, 11:01 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Cool vs Room-temperature Artificial Tears

NCT05832996
View directory record Official record
Conditions
Diabetic Retinopathy With Macular Edema of Both Eyes (Diagnosis), Central Retinal Vein Occlusion With Macular Edema, Exudative Age-Related Macular Degeneration, Unspecified Eye, Cystoid Macular Edema, Ocular Surface Disease, Dry Eye Sensation, Eye Pain
Interventions
Refresh Plus Preservative-free Lubricant Eye Drops
Drug
Lead sponsor
University of Iowa
Other
Eligibility
18 Years to 105 Years
Enrollment
124 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022
U.S. locations
1
States / cities
Iowa City, Iowa
Source: ClinicalTrials.gov public record
Updated Mar 3, 2025 · Synced Jul 21, 2026, 11:01 AM EDT
Completed No phase listed Observational

Resistance to Antibiotics in Patients Receiving Eye Injections

NCT02126423
View directory record Official record
Conditions
Age-Related Macular Degeneration, Retinal Vein Occlusion, Diabetic Retinopathy
Interventions
Conjunctival and nasopharyngeal swabs
Other
Lead sponsor
Prism Vision Group
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014
U.S. locations
1
States / cities
Edison, New Jersey
Source: ClinicalTrials.gov public record
Updated May 31, 2016 · Synced Jul 21, 2026, 11:01 AM EDT
Completed No phase listed Observational

Anatomic Outcomes Following Ozurdex Injections

NCT01282411
View directory record Official record
Conditions
Retinal Vein Occlusions
Interventions
Not listed
Lead sponsor
Barnes Retina Institute
Other
Eligibility
21 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Jul 26, 2016 · Synced Jul 21, 2026, 11:01 AM EDT
Completed Phase 2 Interventional

Research Study in Patients With Persistent Macular Edema

NCT00035906
View directory record Official record
Conditions
Diabetes, Macular Edema, Diabetic Retinopathy, Retinal Disease, Uveitis, Posterior
Interventions
DEX PS DDS®
Drug
Lead sponsor
Allergan
Industry
Eligibility
12 Years and older
Enrollment
315 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2004
U.S. locations
1
States / cities
Sunnyvale, California
Source: ClinicalTrials.gov public record
Updated May 29, 2011 · Synced Jul 21, 2026, 11:01 AM EDT
Terminated Not applicable Interventional Results available

SD-OCT Angiography

NCT02510885
View directory record Official record
Conditions
Neovascular Age-related Macular Degeneration, Age-related Macular Degeneration, Diabetic Retinopathy, Retinal Vein Occlusion, Diabetic Macular Edema
Interventions
AngioVue SD-OCT
Device
Lead sponsor
Duke University
Other
Eligibility
18 Years and older
Enrollment
39 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Apr 18, 2022 · Synced Jul 21, 2026, 11:01 AM EDT
Completed Phase 4 Interventional Results available

Peripheral and Macular Retinal Vascular Perfusion and Leakage in DME and RVO

NCT02503540
View directory record Official record
Conditions
Retinal Vein Occlusion, Diabetic Macular Edema, Branch Retinal Vein Occlusion, Central Retinal Vein Occlusion
Interventions
Aflibercept
Drug
Lead sponsor
Justis Ehlers
Other
Eligibility
18 Years and older
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated May 11, 2021 · Synced Jul 21, 2026, 11:01 AM EDT
Not listed Phase 2 Interventional

5-day Defibrotide Treatment for Hepatic SOS/VOD

NCT04313036
View directory record Official record
Conditions
Sinusoidal Obstruction Syndrome, Veno-occlusive Disease, Bone Marrow Transplant Complications
Interventions
Defibrotide
Drug
Lead sponsor
Loyola University
Other
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
Maywood, Illinois
Source: ClinicalTrials.gov public record
Updated Apr 22, 2021 · Synced Jul 21, 2026, 11:01 AM EDT
Recruiting Early Phase 1 Interventional Accepts healthy volunteers

Feasibility and Safety of MB-102 in Ocular Angiography as Compared to Fluorescein Sodium

NCT04008121
View directory record Official record
Conditions
Retinopathy, Retinal Vein Occlusion, Diabetic Retinopathy, Macular Degeneration
Interventions
Fluorescein sodium and Zeiss FF450 fundus camera, MB-102 and Zeiss FF450 fundus camera, Fluorescein sodium and commercially available optical angiography imaging system, MB-102 and commercially available optical angiography imaging system
Combination Product
Lead sponsor
MediBeacon
Industry
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2026
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Feb 3, 2026 · Synced Jul 21, 2026, 11:01 AM EDT
Completed Phase 3 Interventional

Standard Therapy With or Without Dalteparin in Treating Patients With Advanced Breast, Lung, Colorectal, or Prostate Cancer

NCT00003674
View directory record Official record
Conditions
Breast Cancer, Colorectal Cancer, Lung Cancer, Prostate Cancer, Veno-occlusive Disease
Interventions
dalteparin, standard therapy
Drug
Lead sponsor
Alliance for Clinical Trials in Oncology
Other
Eligibility
18 Years and older
Enrollment
141 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1998 – 2004
U.S. locations
19
States / cities
Scottsdale, Arizona • Urbana, Illinois • Cedar Rapids, Iowa + 16 more
Source: ClinicalTrials.gov public record
Updated Jul 12, 2016 · Synced Jul 21, 2026, 11:01 AM EDT
Not listed Early Phase 1 Interventional

Comfort and Antimicrobial Efficacy of Chlorhexidine vs Betadine for Intravitreal Injections

NCT03571100
View directory record Official record
Conditions
Age-related Macular Degeneration, Diabetic Vascular Diseases, Proliferative Retinopathy, Retina Vein Occlusion
Interventions
Chlorhexidine, Povidine-Iodine
Drug
Lead sponsor
MidAtlantic Retina
Other
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jun 26, 2018 · Synced Jul 21, 2026, 11:01 AM EDT
Terminated Not applicable Interventional Accepts healthy volunteers

Ozurdex Implant for Macular Edema After Treatment Failure With Anti-VEGF

NCT01946399
View directory record Official record
Conditions
Retinal Vein Occlusion (RVO), Macular Edema
Interventions
Ozurdex implant
Drug
Lead sponsor
Retina Research Institute, LLC
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2017
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Dec 1, 2017 · Synced Jul 21, 2026, 11:01 AM EDT
Completed Phase 1 Interventional

Intravitreal v. Sub-tenon Injections of Triamcinolone Acetonide for Macular Edema in Retinal Disorders

NCT00101764
View directory record Official record
Conditions
Macular Degeneration, Retinal Vein Occlusion, Diabetic Retinopathy
Interventions
Triamcinolone Acetonide
Drug
Lead sponsor
National Eye Institute (NEI)
NIH
Eligibility
18 Years and older
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2008
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 1, 2017 · Synced Jul 21, 2026, 11:01 AM EDT
Active, not recruiting Not applicable Interventional Results available

The GORE® VIABAHN® FORTEGRA Venous Stent IVC Study

NCT05409976
View directory record Official record
Conditions
Venous Thromboses, Venous Disease, Venous Leg Ulcer, Venous Stasis, Venous Ulcer, Venous Stenosis, Venous Occlusion, Vein Thrombosis, Vein Occlusion, Vein Disease
Interventions
GORE® VIAFORT Vascular Stent
Device
Lead sponsor
W.L.Gore & Associates
Industry
Eligibility
18 Years and older
Enrollment
136 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2030
U.S. locations
8
States / cities
Stanford, California • Washington D.C., District of Columbia • Chicago, Illinois + 4 more
Source: ClinicalTrials.gov public record
Updated Apr 28, 2026 · Synced Jul 21, 2026, 11:01 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Bevacizumab Versus Ranibizumab in Treatment of Macular Edema From Vein Occlusion

NCT01428388
View directory record Official record
Conditions
Retinal Vein Occlusion, Macular Edema
Interventions
Intravitreal injection of bevacizumab, Intravitreal injection of ranibizumab (0.5 mg per dose)
Drug
Lead sponsor
Barnes Retina Institute
Other
Eligibility
50 Years and older
Enrollment
150 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2015
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Oct 26, 2017 · Synced Jul 21, 2026, 11:01 AM EDT
Completed No phase listed Observational Accepts healthy volunteers Results available

Evaluation of the Precision of the Microperimetry Function of the Spectral OCT/SLO

NCT01692938
View directory record Official record
Conditions
Age-Related Macular Degeneration, Geographic Atrophy, Diabetic Retinopathy, Macular Edema, Retinal Vein Occlusion, Central Serous Retinopathy, Pattern Dystrophy of Macula, Epiretinal Membrane, Macular Hole
Interventions
Not listed
Lead sponsor
Optos, PLC
Industry
Eligibility
21 Years and older
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012
U.S. locations
3
States / cities
Fort Lauderdale, Florida • Baltimore, Maryland • McAllen, Texas
Source: ClinicalTrials.gov public record
Updated May 9, 2017 · Synced Jul 21, 2026, 11:01 AM EDT
Completed Phase 3 Interventional Results available

A Study to Learn How Well a Higher Amount of Aflibercept Given as an Injection Into the Eye Works and How Safe it is in People With Reduced Vision Due to Swelling in the Macula, Central Part of the Retina Caused by a Blocked Vein in the Retina (Macula Edema Secondary to Retinal Vein Occlusion)

NCT05850520
View directory record Official record
Conditions
Macular Edema Secondary to Retinal Vein Occlusion
Interventions
Aflibercept, VEGF Trap-Eye(Eylea, BAY86-5321)_higher dose, Aflibercept, VEGF Trap-Eye(Eylea, BAY86-5321)_2 mg, Sham, Fluorescein
Drug · Diagnostic Test
Lead sponsor
Bayer
Industry
Eligibility
18 Years and older
Enrollment
892 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
53
States / cities
Fullerton, California • Long Beach, California • Mountain View, California + 48 more
Source: ClinicalTrials.gov public record
Updated Jun 16, 2026 · Synced Jul 21, 2026, 11:01 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Philadelphia Telemedicine Glaucoma Detection and Follow-Up Study

NCT02390245
View directory record Official record
Conditions
Glaucoma, Glaucoma Suspect, Diabetic Retinopathy, Ocular Hypertension, Cataract, Branch Retinal Vein Occlusion, Branch Retinal Arterial Occlusion, Central Retinal Vein Occlusion, Central Retinal Artery Occlusion, Epi-retinal Membrane, Macular Degeneration, Drusen, Loss of Vision
Interventions
Free Eye Screenings, Enhanced Intervention, Usual Care
Other
Lead sponsor
Wills Eye
Other
Eligibility
40 Years and older
Enrollment
906 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2020
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Aug 21, 2022 · Synced Jul 21, 2026, 11:01 AM EDT
Completed Phase 2 Interventional

Pegaptanib Sodium Compared to Sham Injection in Patients With Recent Vision Loss Due to Macular Edema Secondary to Central Retinal Vein Occlusion (CRVO)

NCT00088283
View directory record Official record
Conditions
Retinal Vein Occlusion
Interventions
pegaptanib sodium
Drug
Lead sponsor
Eyetech Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2004
U.S. locations
35
States / cities
Tucson, Arizona • Los Angeles, California • Santa Ana, California + 30 more
Source: ClinicalTrials.gov public record
Updated Jan 18, 2007 · Synced Jul 21, 2026, 11:01 AM EDT
Not listed Phase 4 Interventional

Study of Intravitreal Aflibercept Injection for Persistent CRVO-associated Macular Edema Despite Prior Anti-VEGF Therapy

NCT01857544
View directory record Official record
Conditions
Retinal Vein Occlusion
Interventions
Aflibercept
Drug
Lead sponsor
Tennessee Retina
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Oct 28, 2014 · Synced Jul 21, 2026, 11:01 AM EDT
Completed Phase 4 Interventional Results available

Evaluation of Macugen Treatment of Macular Edema Due to Branch Retinal Vein Occlusion

NCT00406107
View directory record Official record
Conditions
Branch Retinal Vein Occlusion
Interventions
pegaptanib sodium (Macugen)
Drug
Lead sponsor
Palmetto Retina Center, LLC
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
3
States / cities
Los Angeles, California • Hagerstown, Maryland • West Columbia, South Carolina
Source: ClinicalTrials.gov public record
Updated Sep 11, 2014 · Synced Jul 21, 2026, 11:01 AM EDT